<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36613612</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Hand-Foot-and-Mouth Disease-Associated Enterovirus and the Development of Multivalent HFMD Vaccines.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">169</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24010169</ELocationID><Abstract><AbstractText>Hand-foot-and-mouth disease (HFMD) is an infectious disease of children caused by more than 20 types of enteroviruses, with most cases recovering spontaneously within approximately one week. Severe HFMD in individual children develops rapidly, leading to death, and is associated with other complications such as viral myocarditis and type I diabetes mellitus. The approval and marketing of three inactivated EV-A71 vaccines in China in 2016 have provided a powerful tool to curb the HFMD epidemic but are limited in cross-protecting against other HFMD-associated enteroviruses. This review focuses on the epidemiological analysis of HFMD-associated enteroviruses since the inactivated EV-A71 vaccine has been marketed, collates the progress in the development of multivalent enteroviruses vaccines in different technical routes reported in recent studies, and discusses issues that need to be investigated for safe and effective HFMD multivalent vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xinglong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Key Laboratory of Systemic Innovative Research on Virus Vaccine, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yifan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Systemic Innovative Research on Virus Vaccine, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Heng</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-6352-2469</Identifier><AffiliationInfo><Affiliation>Key Laboratory of Systemic Innovative Research on Virus Vaccine, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Longding</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1870-0035</Identifier><AffiliationInfo><Affiliation>Key Laboratory of Systemic Innovative Research on Virus Vaccine, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>32070923</GrantID><Agency>the National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>2021-I2M-1-043</GrantID><Agency>CAMS Innovation Fund for Medical Sciences</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005536" MajorTopicYN="Y">Foot-and-Mouth Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">multivalent vaccines</Keyword><Keyword MajorTopicYN="N">systemic immunity</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>8</Day><Hour>1</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36613612</ArticleId><ArticleId IdType="pmc">PMC9820767</ArticleId><ArticleId IdType="doi">10.3390/ijms24010169</ArticleId><ArticleId IdType="pii">ijms24010169</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ang P.Y., Chong C.W.H., Alonso S. Viral determinants that drive Enterovirus-A71 fitness and virulence. Emerg. Microbes Infect. 2021;10:713–724. doi: 10.1080/22221751.2021.1906754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1906754</ArticleId><ArticleId IdType="pmc">PMC8043536</ArticleId><ArticleId IdType="pubmed">33745413</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K., Koike S. Adaptation and Virulence of Enterovirus-A71. Viruses. 2021;13:1661. doi: 10.3390/v13081661.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13081661</ArticleId><ArticleId IdType="pmc">PMC8402912</ArticleId><ArticleId IdType="pubmed">34452525</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Salas E., Francisco-Velilla R., Fernandez-Chamorro J., Lozano G., Diaz-Toledano R. Picornavirus IRES elements: RNA structure and host protein interactions. Virus Res. 2015;206:62–73. doi: 10.1016/j.virusres.2015.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2015.01.012</ArticleId><ArticleId IdType="pubmed">25617758</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-Miragall O., de Quinto S.L., Martínez-Salas E. Relevance of RNA structure for the activity of picornavirus IRES elements. Virus Res. 2009;139:172–182. doi: 10.1016/j.virusres.2008.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2008.07.009</ArticleId><ArticleId IdType="pubmed">18692097</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang S.K., Pestova T.V., Hellen C.U., Witherell G.W., Wimmer E. Cap-independent translation of picornavirus RNAs: Structure and function of the internal ribosomal entry site. Enzyme. 1990;44:292–309. doi: 10.1159/000468766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000468766</ArticleId><ArticleId IdType="pubmed">1966843</ArticleId></ArticleIdList></Reference><Reference><Citation>Francisco-Velilla R., Embarc-Buh A., Abellan S., Martinez-Salas E. Picornavirus translation strategies. FEBS Open Bio. 2022;12:1125–1141. doi: 10.1002/2211-5463.13400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.13400</ArticleId><ArticleId IdType="pmc">PMC9157412</ArticleId><ArticleId IdType="pubmed">35313388</ArticleId></ArticleIdList></Reference><Reference><Citation>Aswathyraj S., Arunkumar G., Alidjinou E.K., Hober D. Hand, foot and mouth disease (HFMD): Emerging epidemiology and the need for a vaccine strategy. Med. Microbiol. Immunol. 2016;205:397–407. doi: 10.1007/s00430-016-0465-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-016-0465-y</ArticleId><ArticleId IdType="pubmed">27406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello A.M., Roshorm Y.M. Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD) Biologicals. 2022;79:1–9. doi: 10.1016/j.biologicals.2022.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2022.08.007</ArticleId><ArticleId IdType="pubmed">36089444</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S., Principi N. Hand, foot and mouth disease: Current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur. J. Clin. Microbiol. Infect. Dis. 2018;37:391–398. doi: 10.1007/s10096-018-3206-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-018-3206-x</ArticleId><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>Légeret C., Furlano R. Oral ulcers in children—A clinical narrative overview. Ital. J. Pediatr. 2021;47:144. doi: 10.1186/s13052-021-01097-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-021-01097-2</ArticleId><ArticleId IdType="pmc">PMC8246667</ArticleId><ArticleId IdType="pubmed">34193212</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassef C., Ziemer C., Morrell D.S. Hand-foot-and-mouth disease: A new look at a classic viral rash. Curr. Opin. Pediatr. 2015;27:486–491. doi: 10.1097/MOP.0000000000000246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOP.0000000000000246</ArticleId><ArticleId IdType="pubmed">26087425</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi E.-J., Shin Y.-J., Kim J.-H., Kim T.-G., Chang S.-Y. Enterovirus 71 infection and vaccines. Clin. Exp. Vaccine Res. 2017;6:4–14. doi: 10.7774/cevr.2017.6.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2017.6.1.4</ArticleId><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinobe R., Wiyatno A., Artika I.M., Safari D. Insight into the Enterovirus A71: A review. Rev. Med. Virol. 2022;32:e2361. doi: 10.1002/rmv.2361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2361</ArticleId><ArticleId IdType="pubmed">35510476</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein M., Chong P. Is a multivalent hand, foot, and mouth disease vaccine feasible? Hum. Vaccines Immunother. 2015;11:2688–2704. doi: 10.1080/21645515.2015.1049780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1049780</ArticleId><ArticleId IdType="pmc">PMC4685682</ArticleId><ArticleId IdType="pubmed">26009802</ArticleId></ArticleIdList></Reference><Reference><Citation>Frydenberg A., Starr M. Hand, foot and mouth disease. Aust. Fam. Physician. 2003;32:594–595.</Citation><ArticleIdList><ArticleId IdType="pubmed">12973865</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand A., Henquell C., Archimbaud C., Ughetto S., Antona D., Bailly J.-L., Peigue-Lafeuille H. Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: A large citywide, prospective observational study. Clin. Microbiol. Infect. 2012;18:E110–E118. doi: 10.1111/j.1469-0691.2012.03789.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2012.03789.x</ArticleId><ArticleId IdType="pubmed">22404077</ArticleId></ArticleIdList></Reference><Reference><Citation>Saguil A., Kane S., Lauters R., Mercado M.G. Hand-Foot-and-Mouth Disease: Rapid Evidence Review. Am. Fam. Physician. 2019;100:408–414.</Citation><ArticleIdList><ArticleId IdType="pubmed">31573162</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak G., Bhuyan S.K., Bhuyan R., Sahu A., Kar D., Kuanar A. Global emergence of Enterovirus 71: A systematic review. Beni Suef Univ. J. Basic Appl. Sci. 2022;11:78. doi: 10.1186/s43088-022-00258-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43088-022-00258-4</ArticleId><ArticleId IdType="pmc">PMC9188855</ArticleId><ArticleId IdType="pubmed">35730010</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhazmi A., Nekoua M.P., Mercier A., Vergez I., Sane F., Alidjinou E.K., Hober D. Combating coxsackievirus B infections. Rev. Med. Virol. 2022:e2406. doi: 10.1002/rmv.2406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2406</ArticleId><ArticleId IdType="pubmed">36371612</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Prinzio A., Bastard D.P., Torre A.C., Mazzuoccolo L.D. Hand, foot, and mouth disease in adults caused by Coxsackievirus B1-B6. An. Bras. Dermatol. 2022;97:321–325. doi: 10.1016/j.abd.2021.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abd.2021.03.012</ArticleId><ArticleId IdType="pmc">PMC9133263</ArticleId><ArticleId IdType="pubmed">35272920</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma V., Goessling L.S., Brar A.K., Eghtesady P. Multiple subtypes of coxsackievirus group B can cause congenital heart disease. Birth Defects Res. 2022 doi: 10.1002/bdr2.2086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bdr2.2086</ArticleId><ArticleId IdType="pubmed">36094067</ArticleId></ArticleIdList></Reference><Reference><Citation>Jmii H., Fisson S., Aouni M., Jaidane H. Type B coxsackieviruses and central nervous system disorders: Critical review of reported associations. Rev. Med. Virol. 2021;31:e2191. doi: 10.1002/rmv.2191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2191</ArticleId><ArticleId IdType="pubmed">33159700</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Jiang L., Zhang C., He W., Tan Y., Ning C. The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine. Vaccine. 2021;39:3319–3323. doi: 10.1016/j.vaccine.2021.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.009</ArticleId><ArticleId IdType="pubmed">33994239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoa-Tran T.N., Dao AT H., Nguyen A.T., Kataoka C., Takemura T., Pham C.H., Vu H.M., Hong T.T.T., Ha N.T.V., Duong T.N., et al. Coxsackieviruses A6 and A16 associated with hand, foot, and mouth disease in Vietnam, 2008–2017: Essential information for rational vaccine design. Vaccine. 2020;38:8273–8285. doi: 10.1016/j.vaccine.2020.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.11.031</ArticleId><ArticleId IdType="pubmed">33223308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H.J., Yoon Y., Lee Y.-P., Kim H.-J., Lee D.-Y., Lee J.-W., Hyeon J.-Y., Yoo J.S., Lee S., Kang C., et al. A Different Epidemiology of Enterovirus A and Enterovirus B Co-circulating in Korea, 2012–2019. J. Pediatric. Infect. Dis. Soc. 2021;10:398–407. doi: 10.1093/jpids/piaa111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piaa111</ArticleId><ArticleId IdType="pubmed">33150450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J., Liu F., Qi H., Tu W., Ward M.P., Ren M., Zhao Z., Su Q., Huang J., Chen X., et al. Changing epidemiology of hand, foot, and mouth disease in China, 2013–2019: A population-based study. Lancet Reg. Health West. Pac. 2022;20:100370. doi: 10.1016/j.lanwpc.2021.100370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2021.100370</ArticleId><ArticleId IdType="pmc">PMC8743221</ArticleId><ArticleId IdType="pubmed">35036978</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan X., Zhang C., Wang X., Ren X., Peng H., Tang X., Zhang L., Chen Z., Ye Y., Zheng M., et al. Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in chengdu, China, 2017–2022: A descriptive study. Emerg. Microbes Infect. 2022;11:2510–2519. doi: 10.1080/22221751.2022.2125346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2125346</ArticleId><ArticleId IdType="pmc">PMC9621254</ArticleId><ArticleId IdType="pubmed">36103331</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., Zhang Z., Rao Q., Wang X., Wang M., Du T., Tang J., Long S., Zhang J., Luo J., et al. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China. Emerg. Microbes Infect. 2021;10:619–628. doi: 10.1080/22221751.2021.1899772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1899772</ArticleId><ArticleId IdType="pmc">PMC8018479</ArticleId><ArticleId IdType="pubmed">33682641</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Chen T., Peng J., Luo Y., Du L., Lu Z., He J., Liu C., Gan Q., Ma W., et al. The spatial-temporal distribution and etiological characteristics of hand-foot-and-mouth disease before and after EV-A71 vaccination in Kunming, China, 2017–2020. Sci. Rep. 2022;12:17028. doi: 10.1038/s41598-022-21312-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-21312-2</ArticleId><ArticleId IdType="pmc">PMC9552732</ArticleId><ArticleId IdType="pubmed">36220850</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty P.C., Turner S.J. The virus-immunity ecosystem. Arch. Virol. Suppl. 2005:17–32. doi: 10.1007/3-211-29981-5_3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/3-211-29981-5_3</ArticleId><ArticleId IdType="pmc">PMC7120975</ArticleId><ArticleId IdType="pubmed">16355866</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J., Van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018;16:368–381. doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Maarouf M., Rai K., Goraya M., Chen J.-L. Immune Ecosystem of Virus-Infected Host Tissues. Int. J. Mol. Sci. 2018;19:1379. doi: 10.3390/ijms19051379.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19051379</ArticleId><ArticleId IdType="pmc">PMC5983771</ArticleId><ArticleId IdType="pubmed">29734779</ArticleId></ArticleIdList></Reference><Reference><Citation>Owino C., Chu J.J.H. Recent advances on the role of host factors during non-poliovirus enteroviral infections. J. Biomed. Sci. 2019;26:47. doi: 10.1186/s12929-019-0540-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0540-y</ArticleId><ArticleId IdType="pmc">PMC6582496</ArticleId><ArticleId IdType="pubmed">31215493</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibaut H.J., De Palma A.M., Neyts J. Combating enterovirus replication: State-of-the-art on antiviral research. Biochem. Pharmacol. 2012;83:185–192. doi: 10.1016/j.bcp.2011.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2011.08.016</ArticleId><ArticleId IdType="pubmed">21889497</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy C., Bowie A.G. Recent insights into innate immune nucleic acid sensing during viral infection. Curr. Opin. Immunol. 2022;78:102250. doi: 10.1016/j.coi.2022.102250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2022.102250</ArticleId><ArticleId IdType="pubmed">36209576</ArticleId></ArticleIdList></Reference><Reference><Citation>Beachboard D.C., Horner S.M. Innate immune evasion strategies of DNA and RNA viruses. Curr. Opin. Microbiol. 2016;32:113–119. doi: 10.1016/j.mib.2016.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mib.2016.05.015</ArticleId><ArticleId IdType="pmc">PMC4983539</ArticleId><ArticleId IdType="pubmed">27288760</ArticleId></ArticleIdList></Reference><Reference><Citation>Damania B., Blackbourn D.J. Innate barriers to viral infection. Future Microbiol. 2012;7:815–822. doi: 10.2217/fmb.12.52.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.12.52</ArticleId><ArticleId IdType="pubmed">22827304</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoshi T., Koyama S., Kobiyama K., Akira S., Ishii K. Innate and adaptive immune responses to viral infection and vaccination. Curr. Opin. Virol. 2011;1:226–232. doi: 10.1016/j.coviro.2011.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2011.07.002</ArticleId><ArticleId IdType="pubmed">22440781</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadler A.J., Williams B.R.G. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 2008;8:559–568. doi: 10.1038/nri2314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2314</ArticleId><ArticleId IdType="pmc">PMC2522268</ArticleId><ArticleId IdType="pubmed">18575461</ArticleId></ArticleIdList></Reference><Reference><Citation>Aw-Yong K.L., NikNadia N.M.N., Tan C.W., Sam I., Chan Y.F. Immune responses against enterovirus A71 infection: Implications for vaccine success. Rev. Med. Virol. 2019;29:e2073. doi: 10.1002/rmv.2073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2073</ArticleId><ArticleId IdType="pubmed">31369184</ArticleId></ArticleIdList></Reference><Reference><Citation>Scutigliani E.M., Kikkert M. Interaction of the innate immune system with positive-strand RNA virus replication organelles. Cytokine Growth Factor Rev. 2017;37:17–27. doi: 10.1016/j.cytogfr.2017.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2017.05.007</ArticleId><ArticleId IdType="pmc">PMC7108334</ArticleId><ArticleId IdType="pubmed">28709747</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff G., Bárcena M. Multiscale Electron Microscopy for the Study of Viral Replication Organelles. Viruses. 2021;13:197. doi: 10.3390/v13020197.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020197</ArticleId><ArticleId IdType="pmc">PMC7912242</ArticleId><ArticleId IdType="pubmed">33525547</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen O.H., Svedin E., Kapell S., Nurminen A., Hytönen V.P., Flodström-Tullberg M. Enteroviral proteases: Structure, host interactions and pathogenicity. Rev. Med. Virol. 2016;26:251–267. doi: 10.1002/rmv.1883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1883</ArticleId><ArticleId IdType="pmc">PMC7169145</ArticleId><ArticleId IdType="pubmed">27145174</ArticleId></ArticleIdList></Reference><Reference><Citation>Maheshwari A., Motta M., Singh S., Kasniya G., Mane S.S., Cartaya S., Rahman M.M., Dudeja P. Enteroviral Infections in Infants. Newborn. 2022;1:297–305. doi: 10.5005/jp-journals-11002-0036.</Citation><ArticleIdList><ArticleId IdType="doi">10.5005/jp-journals-11002-0036</ArticleId><ArticleId IdType="pmc">PMC9599990</ArticleId><ArticleId IdType="pubmed">36304567</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsu B.V., Fay E.J., Nguyen K.T., Corley M.R., Hosuru B., Dominguez V.A., Daugherty M.D. Running With Scissors: Evolutionary Conflicts between Viral Proteases and the Host Immune System. Front. Immunol. 2021;12:769543. doi: 10.3389/fimmu.2021.769543.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.769543</ArticleId><ArticleId IdType="pmc">PMC8591160</ArticleId><ArticleId IdType="pubmed">34790204</ArticleId></ArticleIdList></Reference><Reference><Citation>Verburg S.G., Lelievre R.M., Westerveld M.J., Inkol J.M., Sun Y.L., Workenhe S.T. Viral-mediated activation and inhibition of programmed cell death. PLoS Pathog. 2022;18:e1010718. doi: 10.1371/journal.ppat.1010718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010718</ArticleId><ArticleId IdType="pmc">PMC9371342</ArticleId><ArticleId IdType="pubmed">35951530</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J.A., Hiscox J.A., Solomon T., Ooi M.H., Ng L.F. Immunopathogenesis and Virus-Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease. Front. Microbiol. 2017;8:2249. doi: 10.3389/fmicb.2017.02249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.02249</ArticleId><ArticleId IdType="pmc">PMC5713468</ArticleId><ArticleId IdType="pubmed">29238324</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L., He Y., Chen Y., Kung H.-F., He M.-L. Potent inhibition of human enterovirus 71 replication by type I interferon subtypes. Antivir. Ther. 2011;16:51–58. doi: 10.3851/IMP1720.</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP1720</ArticleId><ArticleId IdType="pubmed">21311108</ArticleId></ArticleIdList></Reference><Reference><Citation>Park N., Schweers N.J., Gustin K.E. Selective Removal of FG Repeat Domains from the Nuclear Pore Complex by Enterovirus 2A(pro) J. Virol. 2015;89:11069–11079. doi: 10.1128/JVI.00956-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00956-15</ArticleId><ArticleId IdType="pmc">PMC4621107</ArticleId><ArticleId IdType="pubmed">26311873</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Xi X., Lei X., Zhang X., Cui S., Wang J., Jin Q., Zhao Z. Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses. PLoS Pathog. 2013;9:e1003231. doi: 10.1371/journal.ppat.1003231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003231</ArticleId><ArticleId IdType="pmc">PMC3605153</ArticleId><ArticleId IdType="pubmed">23555247</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain S.K., Panda S., Sahu B.P., Sarangi R. Activation of Host Cellular Signaling and Mechanism of Enterovirus 71 Viral Proteins Associated with Hand, Foot and Mouth Disease. Viruses. 2022;14:2190. doi: 10.3390/v14102190.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14102190</ArticleId><ArticleId IdType="pmc">PMC9609926</ArticleId><ArticleId IdType="pubmed">36298746</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z., Li H., Zhang Z., Meng J., Mao D., Bai B., Lu B., Mao P., Hu Q., Wang H. Enterovirus 71 2C protein inhibits TNF-α-mediated activation of NF-κB by suppressing IκB kinase β phosphorylation. J. Immunol. 2011;187:2202–2212. doi: 10.4049/jimmunol.1100285.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1100285</ArticleId><ArticleId IdType="pubmed">21810613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Hou H., Wang F., Qiao L., Wang X., Yu J., Liu W., Sun Z. ATP1B3: A virus-induced host factor against EV71 replication by up-regulating the production of type-I interferons. Virology. 2016;496:28–34. doi: 10.1016/j.virol.2016.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.05.013</ArticleId><ArticleId IdType="pmc">PMC7127048</ArticleId><ArticleId IdType="pubmed">27240146</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng C.S., Stobart C.C., Luo H. Innate immune evasion mediated by picornaviral 3C protease: Possible lessons for coronaviral 3C-like protease? Rev. Med. Virol. 2021;31:1–22. doi: 10.1002/rmv.2206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2206</ArticleId><ArticleId IdType="pmc">PMC7883238</ArticleId><ArticleId IdType="pubmed">33624382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace H.L., Russell R.S. Promiscuous Inflammasomes: The False Dichotomy of RNA/DNA Virus-Induced Inflammasome Activation and Pyroptosis. Viruses. 2022;14:2113. doi: 10.3390/v14102113.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14102113</ArticleId><ArticleId IdType="pmc">PMC9609106</ArticleId><ArticleId IdType="pubmed">36298668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Xiao F., Wan P., Pan P., Zhang Y., Liu F., Wu K., Liu Y., Wu J. Correction: EV71 3D Protein Binds with NLRP3 and Enhances the Assembly of Inflammasome Complex. PLoS Pathog. 2018;14:e1006921. doi: 10.1371/journal.ppat.1006921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006921</ArticleId><ArticleId IdType="pmc">PMC5846789</ArticleId><ArticleId IdType="pubmed">29529093</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahand J.S., Salmaninejad A., Mollazadeh S., Zadeh S.S.T., Rezaee M., Sheida A.H., Sadoughi F., Dana P.M., Rafiyan M., Zamani M., et al. Virus, Exosome, and MicroRNA: New Insights into Autophagy. Adv. Exp. Med. Biol. 2022;1401:97–162.</Citation><ArticleIdList><ArticleId IdType="pubmed">35781219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarry M., Vitour D., Zientara S., Kassimi L.B., Blaise-Boisseau S. Foot-and-Mouth Disease Virus: Molecular Interplays with IFN Response and the Importance of the Model. Viruses. 2022;14:2129. doi: 10.3390/v14102129.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14102129</ArticleId><ArticleId IdType="pmc">PMC9610432</ArticleId><ArticleId IdType="pubmed">36298684</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.-H., Wang A., Liu P.-P., Zhang W.-Y., Du J., Xu S., Liu G.-C., Zheng B.-S., Huan C., Zhao K., et al. Divergent Pathogenic Properties of Circulating Coxsackievirus A6 Associated with Emerging Hand, Foot, and Mouth Disease. J. Virol. 2018;92:e00303-18. doi: 10.1128/JVI.00303-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00303-18</ArticleId><ArticleId IdType="pmc">PMC5952127</ArticleId><ArticleId IdType="pubmed">29563294</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui Y., Su J., Wang H., Chang J., Wang S., Zheng W., Cai Y., Wei W., Gordy J.T., Markham R., et al. Disruption of MDA5-Mediated Innate Immune Responses by the 3C Proteins of Coxsackievirus A16, Coxsackievirus A6, and Enterovirus D68. J. Virol. 2017;91:e00546-17. doi: 10.1128/JVI.00546-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00546-17</ArticleId><ArticleId IdType="pmc">PMC5469270</ArticleId><ArticleId IdType="pubmed">28424289</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Yu X., Meng X., Huo W., Su Y., Liu J., Liu Y., Zhang J., Wang S., Yu J. Coxsackievirus A6 Induces Necroptosis for Viral Production. Front. Microbiol. 2020;11:42. doi: 10.3389/fmicb.2020.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.00042</ArticleId><ArticleId IdType="pmc">PMC7011610</ArticleId><ArticleId IdType="pubmed">32117097</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y.M., Zhang Y.L., Bahreyni A., Luo H., Mohamud Y. Coxsackievirus Protease 2A Targets Host Protease ATG4A to Impair Autophagy. Viruses. 2022;14:2026. doi: 10.3390/v14092026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14092026</ArticleId><ArticleId IdType="pmc">PMC9502984</ArticleId><ArticleId IdType="pubmed">36146840</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser L.J., Langereis M.A., Rabouw H.H., Wahedi M., Muntjewerff E.M., de Groot R.J., van Kuppeveld F.J.M. Essential Role of Enterovirus 2A Protease in Counteracting Stress Granule Formation and the Induction of Type I Interferon. J. Virol. 2019;93:e00222-19. doi: 10.1128/JVI.00222-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00222-19</ArticleId><ArticleId IdType="pmc">PMC6498061</ArticleId><ArticleId IdType="pubmed">30867299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels E., Duijsings D., Lanke K.H.W., Melchers W.J.G., Jackson C., van Kuppeveld F.J.M. Molecular determinants of the interaction between coxsackievirus protein 3A and guanine nucleotide exchange factor GBF1. J. Virol. 2007;81:5238–5245. doi: 10.1128/JVI.02680-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02680-06</ArticleId><ArticleId IdType="pmc">PMC1900206</ArticleId><ArticleId IdType="pubmed">17329336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee A., Morosky S.A., Delorme-Axford E., Dybdahl-Sissoko N., Oberste M.S., Wang T., Coyne C.B. The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. PLoS Pathog. 2011;7:e1001311. doi: 10.1371/journal.ppat.1001311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001311</ArticleId><ArticleId IdType="pmc">PMC3059221</ArticleId><ArticleId IdType="pubmed">21436888</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P., Perera R., Cardosa J., Kuhn R.J., Rossmann M.G. Crystal structure of human enterovirus 71. Science. 2012;336:1274. doi: 10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifuente J.O., Lee H., Yoder J.D., Shingler K.L., Carnegie M.S., Yoder J.L., Ashley R.E., Makhov A.M., Conway J.F., Hafenstein S. Structures of the procapsid and mature virion of enterovirus 71 strain 1095. J. Virol. 2013;87:7637–7645. doi: 10.1128/JVI.03519-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03519-12</ArticleId><ArticleId IdType="pmc">PMC3700288</ArticleId><ArticleId IdType="pubmed">23637404</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanongsaksrikul J., Srimanote P., Tongtawe P., Glab-Ampai K., Malik A.A., Supasorn O., Chiawwit P., Poovorawan Y., Chaicumpa W. Identification and production of mouse scFv to specific epitope of enterovirus-71 virion protein-2 (VP2) Arch. Virol. 2018;163:1141–1152. doi: 10.1007/s00705-018-3731-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-018-3731-z</ArticleId><ArticleId IdType="pubmed">29356992</ArticleId></ArticleIdList></Reference><Reference><Citation>Anasir M.I., Poh C.L. Advances in Antigenic Peptide-Based Vaccine and Neutralizing Antibodies against Viruses Causing Hand, Foot, and Mouth Disease. Int. J. Mol. Sci. 2019;20:1256. doi: 10.3390/ijms20061256.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20061256</ArticleId><ArticleId IdType="pmc">PMC6471744</ArticleId><ArticleId IdType="pubmed">30871133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui Y.L.E., Tan T.L., Woo W.H., Timms P., Hafner L.M., Tan K.H., Tan E.L. Enterovirus71 (EV71) utilise host microRNAs to mediate host immune system enhancing survival during infection. PLoS ONE. 2014;9:e102997. doi: 10.1371/journal.pone.0102997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0102997</ArticleId><ArticleId IdType="pmc">PMC4105423</ArticleId><ArticleId IdType="pubmed">25047717</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Zhang L., Wu Z., Tien P. Differential interferon pathway gene expression patterns in Rhabdomyosarcoma cells during Enterovirus 71 or Coxsackievirus A16 infection. Biochem. Biophys. Res. Commun. 2014;447:550–555. doi: 10.1016/j.bbrc.2014.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2014.04.021</ArticleId><ArticleId IdType="pubmed">24735544</ArticleId></ArticleIdList></Reference><Reference><Citation>Pääbo S., Severinsson L., Andersson M., Martens I., Peterson P.A., Nilsson T. Adenovirus proteins and MHC expression. Adv. Cancer Res. 1989;52:151–163.</Citation><ArticleIdList><ArticleId IdType="pubmed">2662711</ArticleId></ArticleIdList></Reference><Reference><Citation>Marongiu L., Valache M., Facchini F.A., Granucci F. How dendritic cells sense and respond to viral infections. Clin. Sci. Lond. 2021;135:2217–2242. doi: 10.1042/CS20210577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20210577</ArticleId><ArticleId IdType="pubmed">34623425</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinjamuri S., Li L., Bouvier M. SARS-CoV-2 ORF8: One protein, seemingly one structure, and many functions. Front. Immunol. 2022;13:1035559. doi: 10.3389/fimmu.2022.1035559.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1035559</ArticleId><ArticleId IdType="pmc">PMC9637571</ArticleId><ArticleId IdType="pubmed">36353628</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Chen Y., Li Y., Huang F., Luo B., Yuan Y., Xia B., Ma X., Yang T., Yu F., et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-I. Proc. Natl. Acad. Sci. USA. 2021;118:e2024202118. doi: 10.1073/pnas.2024202118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024202118</ArticleId><ArticleId IdType="pmc">PMC8201919</ArticleId><ArticleId IdType="pubmed">34021074</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan V., Simoneau C.R., Erickson A.L., Meyers N.L., Baron J.L., Cooper S., McDevitt T.C., Ott M. Modelling T-cell immunity against hepatitis C virus with liver organoids in a microfluidic coculture system. Open Biol. 2022;12:210320. doi: 10.1098/rsob.210320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.210320</ArticleId><ArticleId IdType="pmc">PMC8889170</ArticleId><ArticleId IdType="pubmed">35232252</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang W., Sung P.S., Park S.-H., Yoon S., Chang D.-Y., Kim S., Han K.H., Kim J.K., Rehermann B., Chwae Y.-J., et al. Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector functions. Gastroenterology. 2014;146:1351–1360.e4. doi: 10.1053/j.gastro.2014.01.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2014.01.054</ArticleId><ArticleId IdType="pmc">PMC4478444</ArticleId><ArticleId IdType="pubmed">24486950</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Ou J.-H.J. Hepatitis C virus and intracellular antiviral response. Curr. Opin. Virol. 2022;52:244–249. doi: 10.1016/j.coviro.2021.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2021.12.010</ArticleId><ArticleId IdType="pmc">PMC8844188</ArticleId><ArticleId IdType="pubmed">34973476</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Zhang Y., Zhang X., Hu Y., Dong C., Liu L., Yang E., Che Y., Pu J., Wang X., et al. Pathologic and immunologic characteristics of coxsackievirus A16 infection in rhesus macaques. Virology. 2017;500:198–208. doi: 10.1016/j.virol.2016.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.10.031</ArticleId><ArticleId IdType="pubmed">27829175</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan S., Liao Y., Lian Y., Jiang G., Jiang L., Dong C., Yang E., Wang L., Xu X., Feng M., et al. Erratum: Author Correction: Role of innate lymphoid cells and dendritic cells in intradermal immunization of the enterovirus antigen. NPJ Vaccines. 2019;4:47. doi: 10.1038/s41541-019-0141-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-019-0141-5</ArticleId><ArticleId IdType="pmc">PMC6828669</ArticleId><ArticleId IdType="pubmed">31700692</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan S., Liao Y., Jiang G., Jiang L., Wang L., Xu X., Feng M., Yang E., Zhang Y., Cui W., et al. Study of integrated protective immunity induced in rhesus macaques by the intradermal administration of a bivalent EV71-CA16 inactivated vaccine. Vaccine. 2020;38:2034–2044. doi: 10.1016/j.vaccine.2019.12.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.12.057</ArticleId><ArticleId IdType="pubmed">31982260</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Dong Z., Wang Q., Carr M.J., Li J., Liu T., Li D., Shi W. Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine. 2018;36:7095–7104. doi: 10.1016/j.vaccine.2018.09.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.069</ArticleId><ArticleId IdType="pubmed">30316529</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y.-F., Chou C.-T., Lei H.-Y., Liu C.-C., Wang S.-M., Yan J.-J., Su I.-J., Wang J.-R., Yeh T.-M., Chen S.-H., et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J. Virol. 2004;78:7916–7924. doi: 10.1128/JVI.78.15.7916-7924.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.15.7916-7924.2004</ArticleId><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine E.A., Fuchs J., Das S.C., Partidos C.D., Osorio J.E. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice. Viruses. 2015;7:5919–5932. doi: 10.3390/v7112916.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7112916</ArticleId><ArticleId IdType="pmc">PMC4664989</ArticleId><ArticleId IdType="pubmed">26593938</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Dai W., Zhang C., Zhou Y., Xiong P., Wang S., Ye X., Liu Q., Zhou D., Huang Z. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg. Microbes Infect. 2018;7:94. doi: 10.1038/s41426-018-0094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.-L., Yu C.-I., Hu Y.-C., Tsai T.-J., Kuo Y.-C., Chi W.-K., Lin A.-N., Chiang B.-L. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30:1305–1312. doi: 10.1016/j.vaccine.2011.12.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.081</ArticleId><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone V.M., Hankaniemi M.M., Laitinen O.H., Sioofy-Khojine A.B., Lin A., Lozano I.M.D., Mazur M.A., Marjomäki V., Loré K., Hyöty H., et al. A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci. Adv. 2020;6:eaaz2433. doi: 10.1126/sciadv.aaz2433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2433</ArticleId><ArticleId IdType="pmc">PMC7202868</ArticleId><ArticleId IdType="pubmed">32494709</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone V.M., Hankaniemi M.M., Svedin E., Sioofy-Khojine A., Oikarinen S., Hyöty H., Laitinen O.H., Hytönen V.P., Flodström-Tullberg M. A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia. 2018;61:476–481. doi: 10.1007/s00125-017-4492-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4492-z</ArticleId><ArticleId IdType="pmc">PMC6448957</ArticleId><ArticleId IdType="pubmed">29151123</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazvini K., Keikha M. Multivalent vaccines against new SARS-CoV-2 hybrid variants. Vacunas. 2022 doi: 10.1016/j.vacun.2022.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vacun.2022.06.002</ArticleId><ArticleId IdType="pmc">PMC9212962</ArticleId><ArticleId IdType="pubmed">35757082</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.-C., Guo M.-S., Wu S.-R., Lin H.-Y., Yang Y.-T., Liu W.-C., Chow Y.-H., Shieh D.-B., Wang J.-R., Chong P. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antivir. Res. 2016;129:58–66. doi: 10.1016/j.antiviral.2016.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.02.008</ArticleId><ArticleId IdType="pubmed">26899790</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey T.H., Tang W.K., Butler B., Ouahes T., Orr-Gonzalez S., Salinas N.D., Lambert L.E., Tolia N.H. Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. Sci. Adv. 2022;8:eabq8276. doi: 10.1126/sciadv.abq8276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abq8276</ArticleId><ArticleId IdType="pmc">PMC9473567</ArticleId><ArticleId IdType="pubmed">36103542</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.-C., Chou A.-H., Lien S.-P., Lin H.-Y., Liu S.-J., Chang J.-Y., Guo M.-S., Chow Y.-H., Yang W.-S., Chang K.H.-W., et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29:4362–4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>